Zealand Pharma has spent more than two decades as a peptide shop — small, chemically synthesized chains that have proven extraordinarily productive in cardiometabolic disease. Semaglutide, tirzepatide, and their GLP-1 cousins all share that peptide DNA. But on October 13, the Copenhagen-based company announced it's asking Generate Biomedicines, one of the more technically credible names in generative AI drug design, to help it graduate into a more complex molecular class: multispecific proteins.
Zealand Pharma Bets $1.2B on AI-Designed Proteins to Crack Obesity
Zealand Pharma is partnering with AI drug designer Generate Biomedicines in a deal worth nearly $1.2 billion in milestones, aiming to move beyond peptides into multispecific proteins for metabolic disease. Here's what the deal signals about where obesity drug development is heading next.
This is a Pro article
Subscribe to read the full article and support independent AI journalism.